Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells.
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
Axoskeletal proteins prevent oligodendrocyte from toxic injury by upregulating survival, proliferation, and differentiation in vitro.
Using experimental autoimmune encephalomyelitis as a model to study the effect of prenatal stress on fetal programming.
[Chronically Ill and Unemployed? A Review on Vocational Status in Multiple Sclerosis].
Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins.
MSer – A new, neutral descriptor for someone with multiple sclerosis
Cognitive rehabilitation correlates with the functional connectivity of the anterior cingulate cortex in patients with multiple sclerosis.
Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review.
Multiple Sclerosis: Myeloperoxidase Immunoradiology Improves Detection of Acute and Chronic Disease in Experimental Model.
Multi-compartment t2 relaxometry using a spatially constrained multi-gaussian model.
Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.
[HTLV-1-associated myelopathy/tropical spastic paraparesis : A differential diagnosis in multiple sclerosis.]
Scrub typhus with longitudinally extensive transverse myelitis.
Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis.
Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis.
In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells.
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis - a multicentre cohort study.
Disease Suppression Persists With Ozanimod at 72 Weeks in MS
Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate
Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis.
Biologic therapies: lessons from multiple sclerosis.
Purkinje cell pathology and loss in multiple sclerosis cerebellum.
Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.

Pages